We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$303M
Cap. Flow %
-7.88%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$487M
2
BPMC
Blueprint Medicines
BPMC
+$13.9M
3
ONC
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 45.68%
2 Consumer Discretionary 28.3%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
76
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5M 0.13%
125,000
– –
WHWK
77
Whitehawk Therapeutics
WHWK
$267M
$4.82M 0.13%
103,893
– –
CRSP icon
78
CRISPR Therapeutics
CRSP
$5.22B
$4.43M 0.12%
100,000
+50,000
+100% +$2.62M
AKBA icon
79
Akebia Therapeutics
AKBA
$241M
$4.19M 0.11%
475,000
– –
RCUS icon
80
Arcus Biosciences
RCUS
$3.67B
$4.18M 0.11%
300,000
– –
KDNY
81
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.04M 0.11%
110,000
– –
LJPC
82
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.03M 0.1%
200,000
-50,000
-20% -$1.31M
YMAB
83
DELISTED
Y-mAbs Therapeutics
YMAB
$3.98M 0.1%
+150,000
New +$3.81M
CMRX
84
DELISTED
Chimerix, Inc.
CMRX
$3.89M 0.1%
1,000,000
+500,000
+100% +$2.13M
ELAN icon
85
Elanco Animal Health
ELAN
$11.2B
$3.49M 0.09%
+100,000
New +$3.52M
XENE icon
86
Xenon Pharmaceuticals
XENE
$6.21B
$3.3M 0.09%
250,000
+100,000
+67% +$1.16M
FLEX icon
87
Flex
FLEX
$45.9B
$3.28M 0.09%
+331,750
New +$3.47M
TCDA
88
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.06M 0.08%
100,000
– –
HSTO
89
DELISTED
Histogen Inc. Common Stock
HSTO
$2.9M 0.08%
+2,500
New +$2.3M
GRTS
90
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.85M 0.07%
+200,000
New +$2.85M
SYBX
91
DELISTED
Synlogic
SYBX
$2.84M 0.07%
13,333
-13,334
-50% -$2.11M
VRDN icon
92
Viridian Therapeutics
VRDN
$2.49B
$2.79M 0.07%
33,333
– –
KRYS icon
93
Krystal Biotech
KRYS
$9.72B
$2.64M 0.07%
150,000
– –
NTLA icon
94
Intellia Therapeutics
NTLA
$1.66B
$2.58M 0.07%
90,000
– –
ADVM
95
DELISTED
Adverum Biotechnologies
ADVM
$2.42M 0.06%
40,000
– –
DNTH icon
96
Dianthus Therapeutics
DNTH
$6.13B
$2.4M 0.06%
12,500
– –
QTTB icon
97
Q32 Bio
QTTB
$458M
$2.29M 0.06%
5,556
– –
TGTX icon
98
TG Therapeutics
TGTX
$7.34B
$2.24M 0.06%
400,000
– –
IRWD icon
99
Ironwood Pharmaceuticals
IRWD
$674M
$2.04M 0.05%
131,975
-126,979
-49% -$2.01M
NVAX icon
100
Novavax
NVAX
$1.34B
$940K 0.02%
25,000
– –
1 2 3
4
5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $303M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.